Top Heal Care Stocks To Buy For 2014

Sometimes, you just have to put things in perspective. North Korea's threats to potentially attack the U.S. with nuclear weapons make stock market gyrations seem somewhat trivial. Nonetheless, there were plenty of gyrations to cause worry for some investors over the past few days. Here are three of the week's most horrendous health-care stocks.�

Maybe somebody needs to go to the hospital
Large hospital systems operator Health Management Associates (NYSE: HMA  ) saw its shares fall 13% this week. That's the biggest drop for the stock in four years.�

The company provided a sneak peek at its first quarter results and gave its outlook for the full year on Tuesday. Adjusted admissions were down by 5.7% compared to the same period in 2012. HMA says that the drop appears to be due to fewer uninsured inpatient admissions and higher observation stays where the patient isn't admitted to the hospital.

HMA also revised its full-year earnings down. In January, the company estimated that 2013 earnings could be as high as $1.01 per share. Now, it says the range will be $0.86 to $0.95 per share. At least one analyst, Jefferies and Co.'s Brian Tanquilut, thinks HMA's woes stem partially from a negative 60 Minutes broadcast focusing on the company's emergency department practices.��

Top 10 India Stocks To Watch For 2015: AvWorks Aviation Corp (SPLI)

AvWorks Aviation Corp., formerly Datamill Media Corp., incorporated on January 15, 1990, and its wholly owned subsidiary, Young Aviation, LLC (Young Aviation) operate as a diversified broker and supplier of parts and services to the worldwide aviation and aerospace markets. The Company services a broad range of clients such as aircraft leasing companies, major airlines, repair stations, fixed-base operators, leasing companies and aftermarket suppliers. The Company was a management consulting firm that planned to educate and assist small businesses to improve their management, corporate governance, regulatory compliance and other business processes, with a focus on capital market participation.

On October 3, 2011, the Company acquired 100% interests in Young Aviation. Young Aviation is a diversified broker and supplier of parts, components and products to the general aviation and aerospace markets of the United States, Europe and Asia. Young Aviation services a range of clients, such as aircraft leasing companies, major airlines, repair stations, fixed-base operators, leasing companies and after market suppliers.In December 2011, the Company announced the purchase and salvage of a Lear Jet 24 from a private owner. On June 22, 2011, Datamill Media Sub Corp. was organized as a wholly owned subsidiary of Datamill Media Corp. The principal business of this subsidiary was to act as a merger vehicle for the pending merger with M3X Media, Inc. On August 12, 2011, the Company terminated the Merger Agreement with M3X Media, Inc.

Advisors' Opinion:

• [By James E. Brumley]

  It's a rarity that I reiterate an idea I've previously opined... particularly one that I only published just a couple of days earlier. The fact that I'm going to do so with AvWorks Aviation Corp. (OTCMKTS:SPLI) - perhaps better known to some as Vapor Group - should tell you how important it is to re-convey the message. Here goes...

• [By James E. Brumley]

  It's admittedly scary to try and catch a falling knife, but sometimes it's worth the risk. Case in point? AvWorks Aviation Corp. (OTCMKTS:SPLI) .... better known as Vapor Group. Without knowing more about the stock, the sheer fact that SPLI has fallen nearly 90% since March 26th - with about a third of that coming today alone - the stock would be best left avoided by nearly any trader. For the small group of savvy traders that know the tell-tale signs and know how the market really works, however, AvWorks Aviation, or Vapor Group, may be in a prime buying situation today.... yes, even in the midst of this bloodbath.

Top Heal Care Stocks To Buy For 2014: Xinyuan Real Estate Co Ltd(XIN)

Xinyuan Real Estate Co. Ltd., together with its subsidiaries, engages in residential real estate development in China. The company?s residential projects comprise various residential buildings that include multi-layer apartment buildings, sub-high-rise apartment buildings, or high-rise apartment buildings; auxiliary services and amenities, such as retail outlets, leisure and health facilities, kindergartens, and schools; and small scale residential properties. It also offers property management and other real estate related services, such as landscaping and installing intercom systems. In addition, the company leases properties, including an elementary school, a basement, three clubhouses, five kindergartens, and parking facilities. As of December 31, 2010, it had 21 completed projects with a total gross floor area (GFA) of approximately 2,049,460 square meters and comprising a total of 23,324 units, as well as 8 projects under construction with a total GFA of 1,804,946 sq uare meters. It primarily operates in seven tier II cities, comprising Hefei, Jinan, Kunshan, Suzhou, Zhengzhou, Xuzhou, and Chengdu. The company was founded in 1997 and is headquartered in Beijing, the People?s Republic of China.

Advisors' Opinion:

• [By Tim Brugger]

  Having completed the repurchase of approximately $12.6 million of the $20 million share buyback program started last year, Xinjuan Real Estate's (NYSE: XIN  ) board of directors has authorized the repurchase of an additional $60 million of outstanding stock, the company announced today.

Top Heal Care Stocks To Buy For 2014: Nomura Holdings Inc (NRSCF)

Nomura Holdings, Inc. is engaged in the investment and financial services business with a focus on securities business. The Company's business operations include financing, asset management, securities trading and brokerage, underwriting and sale of securities, private placement of securities, own funds Investment activities, and other securities and finance-related activities. As of March 31, 2013, the Company owned 738 consolidated subsidiaries. Advisors' Opinion:

• [By Daniel Inman]

  Securities firms were in focus in Tokyo after Nomura Holdings (JP:8604) � (NRSCF) �and Daiwa Securities Group (JP:8601) � (DSECF) �reported second-quarter earnings. Daiwa rose 3.4% after reporting its net profit slid 38% on the previous quarter on decreased equity trading, which was above consensus expectations. Analysts say it already is factored into the price.

Top Heal Care Stocks To Buy For 2014: National Oxygen Ltd (NOL)

National Oxygen Limited (NOL) is an India-based company, which is a producer and supplier of industrial gases both in liquid and gaseous forms to industries and hospitals. Its products include oxygen, nitrogen and acetylene. The Company operates in two segments: Industrial Gases, which is engaged in the manufacture of industrial gases, and Windmill, which is engaged in the generation of windmill energy. During the fiscal year ended March 31, 2012 (fiscal 2012), the Company produced 51,07,981 cubic meters of oxygen, 52,138 cubic meters of dissolved acetylene, 30,69,610 cubic meters of nitrogen and 26,86,762 kilowatt hours of windmill energy. It has two industrial gas plants in Tamil Nadu and Pondicherry, and one windmill in Maharashtra. During fiscal 2012, NOL had an installed capacity to produce 2,50,00,000 cubic meters of oxygen, 2,00,000 cubic meters of dissolved acetylene and 44,00,000 kilowatt hours of windmill energy. Advisors' Opinion:

• [By John Emerson]

  Another huge benefit which was imbedded in the value of RTEC was the tens of millions of net operating losses (NOL) that the company had accrued as a result of the massive accrual losses it would sustain during the credit crisis. These benefits were not reflected on the balance sheet but they would translate into tens of millions of dollars in income tax savings when the company eventually returned to profitability.

Top Heal Care Stocks To Buy For 2014: Endocyte Inc.(ECYT)

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics. Its SMDCs target receptors that are over-expressed on diseased cells, relative to healthy cells. The company?s principal SMDC product candidate, EC145, has been evaluated in a randomized Phase II clinical trial for the treatment of women with platinum-resistant ovarian cancer, and it also completed a Phase II single-arm clinical trial for pre-treated non-small cell lung cancer. Its preclinical development products include EC0489 and EC0225, which are in Phase I clinical trial for the treatment of solid cancer tumors; EC17 that has completed Phase I clinical trial for the treatment of solid cancer tumors; EC0531, a tubulysin conjugate to treat solid tumors; and EC0746 and EC0565 foliate receptors for the reduction o f inflammation. The company?s products under development also comprise EC20, a proprietary companion imaging diagnostic product for the identification of folate receptor in cancer patients; EC1069 for prostate cancer therapy; and EC0652 that is in early clinical trials for use as a companion imaging diagnostic for SMDCs. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Equities Trading UP
  Endocyte (NASDAQ: ECYT) shares shot up 121.31 percent to $32.40 after Merck & Co (NYSE: MRK) and Endocyte announced the European CHMP positive opinions for VYNFINIT and the companion agents FOLCEPRI and NEOCEPRI.

• [By Benjamin Paluch]

  Endocyte (ECYT) is a drug development company that seeks to develop small molecule drug candidates (SMDCs) for cancer and other diseases. SMDCs like vintafolide (EC145) are drugs linked to targeting ligands. Targeting ligands are like keys. When they are inserted into the proper lock on a tumor cell, they selectively deliver antitumor compounds. Interestingly, ECYT also develops companion diagnostics in which it links an imaging agent to the same ligand to identify patients likely to respond its therapy. The imaging agent is like a flashlight. It illuminates the lock (tumor cell) to identify the patient as a candidate for drug therapy.

• [By Keith Speights]

  I suspect that the drugs being reviewed by the FDA are more likely than not to receive approval. Merck and partner Endocyte (NASDAQ: ECYT  ) are seeking European approval for ovarian cancer drug vintafolide based on early stage and mid-stage clinical trials only. While the drug shows considerable promise, there is always a risk that authorization could be denied.

Top Heal Care Stocks To Buy For 2014: Ibio Inc (IBIO)

iBio, Inc. (iBio), incorporated on April 17, 2008, is a biotechnology company focused on commercializing its technologies, the iBioLaunch platform for vaccines and therapeutic proteins, as well as the iBioModulator platform for vaccine enhancement. Vaccine candidates on its platform are applicable to newly emerging strains of hemagglutinin type 1 and neuraminidase type 1 (H1N1), swine-like influenza, hemagglutinin type 5 and neuraminidase type 1 (H5N1) avian influenza, yellow fever, and anthrax. The Company licenses or otherwise grants use rights to government and non-governmental organization (NGO) entities for not-for-profit applications of the intellectual property for the development or application for which they granted or were granted funding, and to Fraunhofer USA, Inc. (FhCMB) for research purposes and applications in other fields.

The Company�� platform technology is referred to as iBioLaunch technology or the iBioLaunch platform, and the category of this technology is referred to as plant-based technology or as a plant-based platform. The Company has exclusive control over, and the rights to ownership of, the intellectual property related to all human health and veterinary influenza applications of the plant-based technology developed by FhCMB. Its property consists of the technology platform pursuant, to which hydroponically grown green plants can be used for the accelerated development and manufacture of high-value proteins of interest as candidate therapeutic products and vaccines applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus (HPV), and veterinary influenza applications.

Through FhCMB and their funding from the Bill & Melinda Gates Foundation, it is developing vaccine candidates targeting pathogenic avian influenza (H5N1) viruses based upon the iBioLaunch platform. These candidates have demonstrated immunogenicity and have been successfully tested in mice and ferrets for protective efficacy.! Like its candidate vaccines for seasonal influenza, its candidate vaccines for avian influenza are subunit vaccines. iBio has commercial rights to vaccine candidates developed pursuant to its business structure based on fusing a protein component of HPV called the E7 antigen, to the LicKM protein of the bacterium Clostridium thermocellum. It has commercial rights to an oral anthrax booster vaccine candidate developed by FhCMB in collaboration with the Naval Medical Research Center (NMRC).

Advisors' Opinion:

• [By James E. Brumley]

  With just a quick glance, Ibio Inc. (NYSEMKT:IBIO) doesn't look like anything particularly special. The stock's just bouncing around, and we've not heard any particularly meaningful news from IBIO in a few weeks.

• [By Bryan Murphy]

  If the name Ibio Inc. (NYSEMKT:IBIO) rings a bell, it may be because I put some bullish thoughts into print regarding the stock back on June 21st. I reiterated my optimism on July 12th. What can I say? It's fun to be right. IBIO shares have advanced 17% since my first look in late June. Then again, most of that big jump has unfurled in the last couple of days, meaning Ibio Inc. is overbought. Do we trust the breakout move, or do we fear a pullback? Answer: That depends.

Top Heal Care Stocks To Buy For 2014: LG Display Co Ltd (LPL)

LG Display Co., Ltd. (LG Display), incorporated in 1985, manufactures thin-film transistor liquid crystal display (TFT-LCD) panels in a range of sizes and specifications primarily for use in televisions, notebook computers and desktop monitors, and the Company is a suppliers of high-definition television panels. The Company also manufactures TFT-LCDs for other application products, such as mobile phones, certain types of tablet personal computers and industrial and other applications, including entertainment systems, automotives, portable navigation devices, e-books, digital photo displays and medical diagnostic equipment. During the year ended December 31, 2010, LG Display sold a total of 160.4 million large-size (nine-inch or larger) TFT-LCD panels. In addition to TFT-LCD panels, the Company also manufactures organic light-emitting diode (OLEDs) and flexible displays. As of March 31, 2011, the Company held a total of 15,049 patents, including 6,724 in Korea and 8,325 in other countries, including in the United States, China, Japan, Germany, France, Great Britain and Taiwan.

In May 2010, the Company purchased the liquid crystal display module division of LG Innotek Co., Ltd. (LG Innotek), a subsidiary of LG Electronics. In June 2010, the Company entered into a joint venture agreement with Iriver Ltd. to establish L&I Electronic Technology (Dongguan) Ltd. in Dongguan, China. In August 2010, the Company entered into a joint venture agreement with Everlight Electronics Co., Ltd. and AmTRAN Technology Co., Ltd., to establish Eralite Optoelectronics (Jiangsu) Co., Ltd.

As of December 31, 2010, the Company operated 12 panel fabrication facilities (five in Paju, Korea and seven in Gumi, Korea, and including expansions of certain facilities) and a total of nine module facilities (three in Nanjing, China, two in Guangzhou, China and one each in Gumi and Paju, Korea, Yantai, China and Wroclaw, Poland). In 2010, its display panels were included in products sold by LG Electronics, Appl! e, Toshiba, Dell, Hewlett-Packard, Philips Electronics.

Televisions

The Company�� television panels range from 15 inches to 72-inch wide-format in size. The Company�� product portfolio includes panels of various sizes, such as 17-inch, 19-inch, 20-inch, 22-inch, 26-inch, 32-inch, 37-inch, 42-inch, 47-inch and 55-inch panels.As of december 31, 2010, 32-inch, 37-inch, 42-inch and 47-inch wide-format panels consists of principal products in this category in terms of sales revenue and sales volume.

Desktop Monitors

The Company�� desktop monitor display panels range from 15 inches to 30-inch wide-format in size in a variety of display resolutions and formats. In 2010, 19-inch and 21.5-inch display panels were its principal products in terms of sales revenue and sales volume in this category.

Notebook Computers

The Company�� display panels for notebook computers range from seven inches to 20.1-inch wide-format in size in a variety of display formats. In 2010, 15.6-inch, 9.7-inch and 14-inch panels were its principal products in this category.

Mobile and Other Applications

The Company�� product portfolio also includes panels for mobile and other applications, which utilize a wide array of display panel sizes, including mobile phones, certain types of tablet personal computers and industrial and other applications, including entertainment systems, automotives, portable navigation devices, e-books, digital photo displays and medical diagnostic equipment. TFT-LCD panels that are nine inches and smaller are referred to as small and medium-size panels, with those smaller than four inches being considered small-size panels. In 2010, sales of small-size panels constituted a significant majority in terms of both sales revenue and sales volume in the mobile and other applications category. Some of the panels the Company produces for industrial products, such as medical diagnostic equipment.

T! he Compan! y competes with Samsung Electronics, Samsung Mobile Display and Hydis Technologies, AU Optronics, Chimei Innolux, Chunghwa Picture Tubes, HannStar, Sharp, Hitachi, TMDisplay, Mitsubishi, IPS-Alpha, SAVIC, Infovision and BOE-OT.

Advisors' Opinion:

• [By Steve Sechrist]

  No trouble with the curve
  The curved OLED screens in UHD are top-of-the-line, and LG� (NYSE: LPL  ) and rival Samsung (NASDAQOTH: SSNLF  ) are both expanding the line of spectacular display sets with a 65-inch and 77-inch size, respectively. LG's 77-inch television is a "bendable" version that can transform back to a flat screen when used for ambient viewing of art.�These UHD curved TVs, according to Dr. Ray Soneira of DisplayMate Labs, have marked advantages in that reduce glare and screen reflection from bright images behind the user. Curved displays "substantially" improve performance and are "no marketing gimmick," according to Soneira's technology review.�